|Page (1) of 1 - 06/13/18||email article||print page|
(June 13, 2018)
Chordoma is a rare type of primary bone cancer that is typically malignant in nature. This type of tumor occurs mostly at the skull base or along the spine. These tumors are formed from small fragments of embryonic cells that accumulate into the disks of the spinal column. The prevalence is found to be twice in men in comparison with women. Moreover, most of the tumor cases occur between the age group of 50 to 70 years.
According to the American Cancer Society, over 40% of primary bone cancers are chondrosarcomas. The maximum prevalence is given to osteosarcomas (28%), followed by chordomas (10%), Ewing tumors (8%), and malignant fibrous histiocytoma (4%). About two out of five chordomas (40%) propagate in the skull region, while the rest develop in the bones of the spine.
View Reports Sample @ https://www.marketresearchfuture.com/sample_request/5784
The preferred surgical treatment for chordomas of the skull base is Endoscopic Endonasal Approach (EEA) developed by UPMC. This minimally invasive technique uses nasal cavities as a corridor to reach the inoperable tumors. The benefits of EEA surgeries include no incisions to heal, no disfigurement, and faster recovery.
The increasing occurrence of bone cancer along with growing government initiatives for bone cancer awareness and aging population globally are the major factors expected to fuel the global chordoma disease market over the forecast period.
Global Market for the Chordoma Disease is expected to grow at a CAGR of approximately 6.8% during 2017 to 2023.
- Chordoma drug manufacturers
- Chordoma drug suppliers
- Biotechnology companies
- Government institutes
- Research and development companies
- Academic medical centers and universities
- Research and consulting firms
- Venture capital firms
The global chordoma disease market has been segmented on the basis of diagnosis, treatment, and end-user.
On the basis of diagnosis, the global chordoma disease market is segmented into biopsy, imaging, blood tests, and others. The imaging segment is further divided into x-ray, Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, Positron Emission Tomography (PET) scanning, and bone scan.
On the basis of treatment, the global chordoma disease market is segmented into chemotherapy, radiation therapy, cryosurgery, surgical treatments, radiosurgery, targeted therapy, and others. The surgery segment is further classified into radical resections, sacral chordoma, spinal chordoma, skull base chordoma, and others. The chemotherapy segment is classified into methotrexate, doxorubicin, and others. Furthermore, the targeted therapy segment is divided into bevacizumab, erlotinib, and others.
On the basis of end-user, the global chordoma disease market is segmented into hospitals, clinics, cancer care centers, and others.
Report with Discount Available @ https://www.marketresearchfuture.com/check-discount/5784
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
2.2 Scope Of The Study
2.2.1 Research Objective
Chapter 3. Research Methodology
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.5 Macroeconomic Indicators
4.6 Disease Indication Trends & Assessment
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Request Full Report @ https://www.marketresearchfuture.com/reports/chordoma-disease-market-5784
Some of the key players in the global chordoma disease market are AstraZeneca plc (U.K.), Amgen, Inc. (U.S.), Actavis plc (U.S.), Bristol-Myers Squibb and Company (U.S.), Celgene Corporation (U.S.), Eli Lilly and Company (U.S.), F. Hoffmann-La Roche AG (Switzerland), GlaxoSmithKline plc (UK), Novartis International AG (Switzerland), Pfizer, Inc. (U.S.), Sanofi S.A. (France), Debiopharm Group (Switzerland), Bayer AG (Germany), Johnson & Johnson (U.S.), Merck & Co., Inc. (U.S.), Optivus Proton Therapy, Inc. (U.S.), ProCure Treatment Centers, Inc. (U.S.), Varian Medical Systems, Inc.(U.S.), Amura Holdings Ltd. (U.S.), Catena pharmaceuticals Inc. (U.S.), Celldex therapeutics Inc. (U.S.), Eckert & Ziegler BEBIG (Germany), Infinity Pharmaceuticals (U.S.), Medivir AB (Sweden), Merrion Pharmaceuticals Plc. (U.S.), and others.
Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
Company Name: Market Research Future
Contact Person: Abhishek Sawant
Email: [email protected]
Phone: +1 646 845 9312
Address:Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar
Related Keywords:Business,Health & Medicine,Pharmaceuticals & Biotech,Science,World,
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter